MENGENAI EPISOD INI
View the Show Notes Page for This Episode
Become a Member to Receive Exclusive Content
Sign Up to Receive Peter's Weekly Newsletter
In this episode, Peter returns to the topic of peptides, offering a clear and accessible guide to a field surrounded by both genuine scientific promise and widespread misinformation. Peptides are increasingly marketed for everything from injury recovery and muscle growth to longevity and improved appearance, often with claims that extend far beyond the available evidence. Rather than promoting or dismissing peptides as a category, Peter presents a practical framework for evaluating any peptide: what it is, how it is supposed to work, and where the science is strong, weak, or simply absent. He then applies this framework to a specific example before examining the risks of gray-market products, concerns about sourcing and quality, and where the field may be headed—ultimately helping listeners distinguish legitimate therapies from hope that has been packaged and sold without sufficient evidence.
We discuss:
- What peptides are and why they must be evaluated individually [3:15];
- A five-question framework for evaluating peptides and other drugs [5:30];
- A three-tier system for classifying the scientific evidence behind peptides [10:00];
- Evaluating BPC-157: unclear mechanisms, absent human evidence, and unknown risks [14:00];
- Why BPC-157's expanding claims do not indicate a broad mechanism [20:45];
- CJC-1295: biological activity versus meaningful clinical benefit [23:30];
- Why testimonials about peptide benefits cannot establish the effectiveness of peptides [27:30];
- The placebo effect, and the importance of controlled trials for evaluating peptides [31:00];
- What FDA approval provides when evaluating peptide safety and effectiveness [34:45];
- Why prescriptions from doctors, compounding pharmacies, and third-party testing do not validate unapproved peptides [38:30];
- Approved peptides sold on the gray market: why evidence for an approved peptide does not automatically extend to gray-market versions [40:45];
- Addressing the claim that pharmaceutical companies ignore effective natural peptides because they cannot be patented [43:00];
- The promise of peptide science, and the risks of the gray-market wellness industry [46:30];
- Why peptide claims must be falsifiable and why evidence should precede widespread use rather than be expected to catch up later [49:00]; and
- More.
Connect With Peter on Twitter, Instagram, Facebook and YouTube
